Hans C Lee
Overview
Explore the profile of Hans C Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1852
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Marcoux C, Pasvolsky O, Milton D, Tanner M, Bashir Q, Srour S, et al.
Transplant Cell Ther
. 2024 Oct;
31(1):12.e1-12.e10.
PMID: 39448031
Despite tremendous advancements in multiple myeloma (MM) therapeutics, outcomes remain heterogeneous, heavily influenced by clinical and cytogenetic factors. Among these, deletion of the short arm of chromosome 17 (del(17p)) is...
12.
Hultcrantz M, Kleinman D, Vij R, Escalante F, Delforge M, Kotowsky N, et al.
Haematologica
. 2024 Oct;
110(3):753-757.
PMID: 39415693
No abstract available.
13.
Szymura S, Wang L, Zhang T, Cha S, Song J, Dong Z, et al.
Nat Commun
. 2024 Aug;
15(1):6874.
PMID: 39128904
Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade lymphoma with no standard therapy. Nine asymptomatic patients treated with a first-in-human, neoantigen DNA vaccine experienced no dose limiting toxicities (primary endpoint, NCT01209871)....
14.
Abonour R, Lee H, Rifkin R, Ailawadhi S, Omel J, Hardin J, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jul;
24(10):e336-e343.
PMID: 39033038
Background: Lenalidomide (R), bortezomib (V), and dexamethasone (d) is a standard-of-care regimen in newly diagnosed multiple myeloma (NDMM); however, characteristics and outcomes for nontransplanted patients receiving frontline RVd are not...
15.
Shah J, Devalaraju S, Baerman E, Lee I, Takigawa K, Machado A, et al.
J Cancer Res Clin Oncol
. 2024 Jul;
150(7):334.
PMID: 38969842
Purpose: Proteasome inhibitors (PIs), which cause cell death via tumor suppressor and pro-apoptotic proteins, are integral to treatment of many hematologic malignancies but are limited by their gastrointestinal adverse effects....
16.
Bumma N, Richter J, Jagannath S, Lee H, Hoffman J, Suvannasankha A, et al.
J Clin Oncol
. 2024 Jun;
42(22):2702-2712.
PMID: 38879802
Purpose: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody...
17.
Pasvolsky O, Marcoux C, Dai J, Milton D, Tanner M, Syed N, et al.
Transplant Cell Ther
. 2024 Jun;
30(8):772.e1-772.e11.
PMID: 38852784
Upfront autologous stem cell transplantation (auto-SCT) remains standard of care for eligible patients with newly diagnosed multiple myeloma (NDMM), although recently its role has been questioned. The aim of the...
18.
Pasvolsky O, Wang Z, Milton D, Tanner M, Bashir Q, Srour S, et al.
Blood Cancer J
. 2024 May;
14(1):82.
PMID: 38760362
Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve a durable response....
19.
Lee H, Ramasamy K, Macro M, Davies F, Abonour R, van Rhee F, et al.
Eur J Haematol
. 2024 Apr;
113(2):190-200.
PMID: 38654611
Objectives: To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM). Methods:...
20.
Alzahrani K, Pasvolsky O, Wang Z, Milton D, Tanner M, Bashir Q, et al.
Br J Haematol
. 2024 Mar;
204(5):1944-1952.
PMID: 38448009
The second revision of the International Staging System (R2-ISS) is a simple tool to risk-stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the...